C4 Therapeutics, Inc. CCCC
C4 Therapeutics, Inc. (Nasdaq: CCCC) is an oncology drug developer. Its lead program, cemsidomide (IKZF1/3 degrader), is in Phase 2 for relapsed/refractory multiple myeloma. Its next catalyst on record is cemsidomide + elranatamab: Dose escalation progress update (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: cemsidomide + elranatamab — Dose escalation progress update (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| cemsidomide + dexamethasone (MOMENTUM) | relapsed/refractory multiple myeloma | small molecule | Phase 2 |
| cemsidomide + dexamethasone + elranatamab (Pfizer agreement) | multiple myeloma, earlier lines | small molecule | Phase 1 |
| cemsidomide combos with daratumumab or carfilzomib | multiple myeloma | small molecule | Phase 1 |
| CFT8919 (Betta Pharma, Greater China) | EGFR L858R NSCLC | small molecule | Phase 1 |
| inflammation/neuroinflammation/neurodegeneration degraders | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.